<DOC>
	<DOCNO>NCT00462657</DOCNO>
	<brief_summary>RATIONALE : Studying way diagnose fungal infection early may help doctor plan best treatment . PURPOSE : This clinical trial study laboratory test see well find aspergillosis early patient high risk fungal infection cause treatment hematologic cancer disease .</brief_summary>
	<brief_title>Early Diagnosis Aspergillosis Patients High Risk Fungal Infection Caused Treatment Hematologic Cancer Other Disease</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine test characteristic galactomannan ( GM ) ELISA use serum bronchoalveolar lavage fluid ( BALF ) collect patient high risk invasive fungal infection . - Determine test characteristic aspergillus PCR use blood BALF sample collect patient . - Evaluate role noninvasive exhale breath condensate ( EBC ) detect invasive aspergillosis ( IA ) . - Determine whether repeat measure time combination marker improve test characteristic . - Establish cutoff point diagnosis IA . Secondary - Determine inflammatory marker cytokine profile EBC fungal infection bone marrow transplantation marker acute lung injury . - Assess role bronchoscopy bronchoalveolar lavage identify causal pathogen early disease course febrile neutropenic patient . - Assess role GM ELISA prognosis response treatment IA . - Assess role aspergillus PCR prognosis response treatment IA . OUTLINE : This prospective study . Patients assess early diagnosis invasive aspergillosis ( IA ) use serum bronchoalveolar lavage fluid ( BALF ) evaluate ELISA galactomannan ( GM ) antigen real time PCR fungal DNA . Serum sample collect baseline periodically study , begin onset neutropenia continue resolution fever recovery neutrophil count . BALF sample collect patient abnormal chest radiology evaluate bronchoscopy bronchoalveolar lavage . BALF analyze GM antigen , fungal DNA , inflammatory marker , cytokine . Patients also assess use exhale breath condensate ( EBC ) evaluate GM ELISA real time PCR . EBC collect baseline periodically study detect GM antigen fungal DNA measure marker pulmonary inflammation oxidative stress ( e.g. , pH , hydrogen peroxide , leukotriene B4 ) . PROJECTED ACCRUAL : A total 200 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At high risk develop invasive aspergillosis ( IA ) due follow risk factor : Diagnosis acute myeloid leukemia , myelodysplastic syndrome , acute lymphoblastic leukemia AND meet ≥ 1 follow criterion : Receiving intensive chemotherapy expect duration neutropenia ( ANC &lt; 500/mm³ ) &gt; 10 day Receiving highdose steroid Concurrent treatment allogeneic hematopoietic stem cell transplantation ( HSCT ) Requirement highdose steroid graftversushost disease HSCT History probable proven IA receive chemotherapy No preexisting chest disease PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>infection</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
</DOC>